Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
ITRM Price/Volume Stats
| Current price | $0.66 | 52-week high | $2.05 |
| Prev. close | $0.72 | 52-week low | $0.60 |
| Day low | $0.65 | Volume | 25,300 |
| Day high | $0.72 | Avg. volume | 59,408 |
| 50-day MA | $0.93 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 8.61M |
ITRM Stock Price Chart Interactive Chart >
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Latest ITRM News From Around the Web
Below are the latest news stories about ITERUM THERAPEUTICS PLC that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
Q2 2023 Iterum Therapeutics PLC Earnings CallQ2 2023 Iterum Therapeutics PLC Earnings Call |
Iterum Therapeutics Reports Second Quarter 2023 Financial Results--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2023. |
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Friday, August 11, 2023. Management will h |
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news. |
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From SantheraCatalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review. |
ITRM Price Returns
| 1-mo | -25.84% |
| 3-mo | -35.92% |
| 6-mo | -33.68% |
| 1-year | -59.76% |
| 3-year | -93.23% |
| 5-year | -99.31% |
| YTD | -21.43% |
| 2022 | -85.71% |
| 2021 | -60.38% |
| 2020 | -78.02% |
| 2019 | -10.18% |
| 2018 | N/A |
Continue Researching ITRM
Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...